These data support previous studies that CHIP may also contribute to disease progression in solid tumors and therapy-related neoplasms and suggest that obesity may be an important risk factor in these patient populations (6, 80–84). The gene discussed is STUB1; the disease is obesity due to melanocortin 4 receptor deficiency.